NewsBenzingaBioNTech Reports AHEAD-MERIT Phase 2/3 Clinical Trial Did Not Meet First Dual Primary Endpoint Of Progression-Free Survival For mRNA Cancer Immunotherapy Candidate BNT113 Plus Pembrolizumab Compared With Pembrolizumab Alone BioNTech Reports AHEAD-MERIT Phase 2/3 Clinical Trial Did Not Meet First Dual Primary Endpoint Of Progression-Free Survival For mRNA Cancer Immunotherapy Candidate BNT113 Plus Pembrolizumab Compared With Pembrolizumab Alone Benzinga 2026.10.13 10:47 (GMT+0) Open on Benzinga Other news Next Week's Macro Outlook: Fed Enters Blackout Period, US Earnings Season Hits Its Stride US AI-concept stock perpetual contracts plunged in early morning; Micron and SK Hynix fell over 6% PDS Biotechnology Corporation (PDSB) Discusses PDS-0301 Immunocytokine and Its Role in Treating Metastatic Colorectal Cancer - Slideshow (NASDAQ:PDSB) 2026-10-17 What to Expect From Advanced Micro Devices’ Q3 2026 Earnings Report Here's What to Expect From Uber’s Next Earnings Report Aflac’s Q3 2026 Earnings: What to Expect
PDS Biotechnology Corporation (PDSB) Discusses PDS-0301 Immunocytokine and Its Role in Treating Metastatic Colorectal Cancer - Slideshow (NASDAQ:PDSB) 2026-10-17
